Abstract

Many translational cancer research studies are based on the study of human cancer tissues. This research requires access to samples of human cancers and corresponding normal tissues and also requires expertise of qualified pathologists to assist in the appropriate use of tissues and interpretation of results. The purpose of this core is to provide a centralized resource for collecting and processing samples of solid tumors and hematologic malignancies based on the needs of Cancer Center investigators. The procurement of solid tumor tissues by the Core frequently involves selection of appropriate paraffin tissue blocks as well as collection of fresh-frozen tissue samples. The Core also provides a centralized laboratory resource for conducting immunohistochemistry, and in response to increased requests for immunochemistry on breast cancer samples, is developing breast cancer tissue arrays. Finally, the Core provides consultative services for the assessment of tissue samples and the development and interpretation of immunohistochemistry assays.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006973-39
Application #
6481450
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
1978-01-01
Project End
2006-04-30
Budget Start
Budget End
Support Year
39
Fiscal Year
2001
Total Cost
Indirect Cost

  Institution

Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218

  Publications

Giraldo, Nicolas A; Nguyen, Peter; Engle, Elizabeth L et al. (2018) Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. J Immunother Cancer 6:99
Barberi, Theresa; Martin, Allison; Suresh, Rahul et al. (2018) Absence of host NF-?B p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. Cancer Immunol Immunother 67:1491-1503
Taube, Janis M; Galon, Jérôme; Sholl, Lynette M et al. (2018) Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 31:214-234
Krueger, Timothy E G; Thorek, Daniel L J; Denmeade, Samuel R et al. (2018) Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Transl Med 7:651-663
Boudadi, Karim; Suzman, Daniel L; Anagnostou, Valsamo et al. (2018) Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget 9:28561-28571
Dean, Lorraine T; Gehlert, Sarah; Neuhouser, Marian L et al. (2018) Social factors matter in cancer risk and survivorship. Cancer Causes Control 29:611-618
Yuan, Ming; Da Silva, Ana Cristina A L; Arnold, Antje et al. (2018) MicroRNA (miR) 125b regulates cell growth and invasion in pediatric low grade glioma. Sci Rep 8:12506
Jacobs, Michael A; Macura, Katarzyna J; Zaheer, Atif et al. (2018) Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors. Acad Radiol 25:1405-1414
Annesley, Colleen E; Rabik, Cara; Duffield, Amy S et al. (2018) Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice. Oncotarget 9:35313-35326
Liu, Tao; Ivaturi, Vijay; Sabato, Philip et al. (2018) Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship. Clin Transl Sci 11:435-443

Showing the most recent 10 out of 2393 publications